AlloVir stockholders elect Sinha and Brenner as Class II directors; ratify Deloitte

Kalaris Therapeutics, Inc.

Vikas Sinha elected with 47,229,880 for, 4,036,755 withhold, 10,745,678 broker non-votes.
Malcolm Brenner elected with 48,449,496 for, 2,817,139 withhold, 10,745,678 broker non-votes.
Ratification of Deloitte & Touche as auditor approved: 61,754,011 for, 250,317 against, 7,985 abstain.

item 5.07

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-155023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.